Once binding capacity is lost the molecule cannot do what it was prescribed to do, which is why temperature is a potency issue rather than a convenience one
If you are not sure whether you should be given this medicine, talk to your doctor
By type of agonist the market is single-agonist, dual-agonist and tri-agonist, by route of administration market is categorized into oral and parenteral, by target indication market is categorized into Alzheimers disease, non-alcoholic steatohepatitis, obesity, sleep apnea, type 2 diabetes
Here come the lawyers Despite Novo Nordisks strategy of making clear how fragile generic supply chains are (a goal I share), I was surprised it took the pharma company so long to go after Hims & Hers specifically (maybe the lawyers were too busy saying that no, they meant to let their Canadian patent expire)